Effect of Calcium and Vitamin D on Bone Loss From the Hip

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Tufts University
ClinicalTrials.gov Identifier:
NCT00357643
First received: July 26, 2006
Last updated: NA
Last verified: June 2005
History: No changes posted

July 26, 2006
July 26, 2006
October 1992
Not Provided
Bone Density of the hip
Same as current
No Changes Posted
  • Annual and Seasonal patterns of change in bone mineral density of the hip
  • Associations between biochemical, physical and life-style factors
  • Examine influence of clinical status, lifestyle, medication use and season on the occurrence of falls
Same as current
Not Provided
Not Provided
 
Effect of Calcium and Vitamin D on Bone Loss From the Hip
Effect of Calcium and Vitamin D on Bone Loss From the Hip

The primary aim of this study is to determine the effects of supplementation with both calcium and vitamin D on changes in bone density of the hip in men and women age 65 and older.

In this study 445 men and women age 65 and older were enrolled for three years each. Subjects were randomized to treatment with 500 mg of calcium s calcium citrate malate plus 700 IU of vitamin D daily or placebo. Subjects came to the research center every six months for biochemical and bone mineral density measurements. Changes in these measures over the three years were determined in each group and compared.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Osteoporosis
Drug: Calcium 500 mg/day and vitamin D 700 IU/day
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
450
February 1996
Not Provided

Inclusion Criteria:

>65 years calcium intake < 1500 mg/day Willing to discontinue calcium and vitamin D pills for 2 months prior to enrollment

Exclusion Criteria:

Mentally incompetent, femoral neck BMD greater than 2 SD above/below age/sex-matched reference mean, 24-hr urine calcium/creatinine > 300 mg/d women or >350 mg/d men terminal illness, renal disease requiring treatment, kidney stone in the past 10 years, current hyperparathyroidism, treated with glucocorticoids, estrogen or androgen, fluoride, calcitonin, bisphosphonate, or any other treatment for osteoporosis.

Both
65 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00357643
U01AG010353
Not Provided
Not Provided
Tufts University
National Institutes of Health (NIH)
Principal Investigator: Bess Dawson-Hughes, MD Tufts University
Tufts University
June 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP